Article
NeurologyLive Friday 5 — February 7, 2020
Author(s):
Take 5 minutes to catch up on NeurologyLive's highlights from the week ending February 7, 2020.
Welcome to NeurologyLive's Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive's widespread coverage in neurology, ranging from newsworthy study findings and FDA action to expert interviews and peer-to-peer panel discussions.
1: Risdiplam Effective in Spinal Muscular Atrophy Type 2 and 3
The study is the first placebo-controlled trial to include non-ambulant adults with spinal muscular atrophy type 2 or 3.
2: Fenfluramine Shows Success in Lennox-Gastaut Phase 3 Topline Data
The investigational therapy met its primary end point, showing superiority to placebo in reducing the frequency of drop seizures in patients with Lennox-Gastaut syndrome.
3: Sanofi's Investigational Multiple Sclerosis Drug Reduces Disease Activity
Sanofi observed a dose-response relationship based on reduction of new active gadolinium-enhancing T1-hyperintense lesions after 12 weeks of treatment with SAR442168.
4: Ultrasound-Guided vs Anatomical-Localization of Injectables
Comparing accuracy of ultrasound-guided vs anatomical localization of botulinum toxic injections into cadaver salivary glands.
5: Smartphone Videos May Be Reliable Resource to Aid Seizure Diagnosis
Recently published data showed that one-quarter of the smartphone videos were correctly diagnosed by 100% of the reviewing physicians.
